Skip to main content
Erschienen in: Wiener klinische Wochenschrift 13-14/2017

01.07.2017 | original article

Clinical role of von Willebrand factor in acute ischemic stroke

verfasst von: Marija Menih, MD, Miljenko Križmarić, PhD, Tanja Hojs Fabjan, MD, PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 13-14/2017

Einloggen, um Zugang zu erhalten

Summary

Background

An elevated level of von Willebrand factor (VWF) is associated with an increased risk for coronary heart disease and ischemic stroke. The objective of the study was to determine whether the level of VWF is associated with the cardioembolic subtype of ischemic stroke, stroke severity, and clinical outcome.

Patients and methods

In this study 108 patients suffering from acute ischemic stroke (AIS) were included. According to the etiology of the stroke, patients were classified into the subtype of cardioembolic (CE) stroke and the group with non-CE stroke. Patients with non-CE stroke were further classified into subtype of large vessel disease, subtype of small vessel disease and subtype of cryptogenic stroke. Laboratory tests were performed in the acute phase and VWF was determined for all patients. The National Institutes of Health Stroke Scale (NIHSS) was applied on admission and the modified Rankin scale (MRS) at discharge.

Results

The only significant factor which predicted CE stroke was age (B = 0.077; standard error, SE = 0.026; P = 0.003). The level of VWF was not significantly higher in the group with the cardioembolic stroke compared to the group with non-CE stroke. Patients assessed by NIHSS on admission as the most disabled had significantly higher levels of VWF (B = 0.006; SE = 0.003; P = 0.045). Those with higher scores of MRS at discharge also had significantly increased levels of VWF (B = 0.006; SE = 0.003; P = 0.028).

Conclusion

Among the patients with ischemic stroke, levels of VWF were not increased in those with CE stroke. High levels of VWF were associated with greater severity of stroke as well as with poor clinical outcome.
Literatur
2.
Zurück zum Zitat Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 1993;70(3):380–5.PubMed Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 1993;70(3):380–5.PubMed
3.
Zurück zum Zitat Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood. 2006;107(9):3537–45.CrossRefPubMedPubMedCentral Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood. 2006;107(9):3537–45.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular disease. Focus on acute coronary syndromes. Circulation. 2008;117(11):1449–59.CrossRefPubMed Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular disease. Focus on acute coronary syndromes. Circulation. 2008;117(11):1449–59.CrossRefPubMed
5.
Zurück zum Zitat Vischer UM. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186–93.CrossRefPubMed Vischer UM. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186–93.CrossRefPubMed
6.
Zurück zum Zitat Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151–6.CrossRefPubMed Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151–6.CrossRefPubMed
7.
Zurück zum Zitat Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007;38(6):1873–80.CrossRefPubMed Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007;38(6):1873–80.CrossRefPubMed
8.
Zurück zum Zitat Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9(2):275–81.CrossRefPubMed Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9(2):275–81.CrossRefPubMed
9.
Zurück zum Zitat Sonneveld MA, van Dijk AC, van den Herik EG, van Loon JE, de Lau LM, van der Lugt A, et al. Relationship of von Willebrand factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis. 2013;230(2):210–5.CrossRefPubMed Sonneveld MA, van Dijk AC, van den Herik EG, van Loon JE, de Lau LM, van der Lugt A, et al. Relationship of von Willebrand factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis. 2013;230(2):210–5.CrossRefPubMed
10.
Zurück zum Zitat Kraft P, Drechsler C, Gunreben I, Nieswandt B, Stoll G, Heuschmann PU, et al. Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. PLOS ONE. 2014;9(6):e99851.CrossRefPubMedPubMedCentral Kraft P, Drechsler C, Gunreben I, Nieswandt B, Stoll G, Heuschmann PU, et al. Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. PLOS ONE. 2014;9(6):e99851.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke. 2012;43(2):599–606.CrossRefPubMed De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke. 2012;43(2):599–606.CrossRefPubMed
12.
Zurück zum Zitat Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115(17):2323–30.CrossRefPubMed Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115(17):2323–30.CrossRefPubMed
13.
Zurück zum Zitat Le Behot A, Gauberti M, Martinez De Lizarrondo S, Montagne A, Lemarchand E, Repesse Y, et al. GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood. 2014;123(21):3354–63.CrossRefPubMed Le Behot A, Gauberti M, Martinez De Lizarrondo S, Montagne A, Lemarchand E, Repesse Y, et al. GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood. 2014;123(21):3354–63.CrossRefPubMed
14.
Zurück zum Zitat Momi S, Tantucci M, Van Roy M, Ulrichts H, Ricci G, Gresele P. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013;121(25):5088–97.CrossRefPubMed Momi S, Tantucci M, Van Roy M, Ulrichts H, Ricci G, Gresele P. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013;121(25):5088–97.CrossRefPubMed
15.
Zurück zum Zitat Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41.CrossRefPubMed Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41.CrossRefPubMed
16.
Zurück zum Zitat The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRef The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRef
17.
Zurück zum Zitat Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke. 2002;33(9):2243–6.CrossRefPubMed Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke. 2002;33(9):2243–6.CrossRefPubMed
18.
Zurück zum Zitat Zareba W, Pancio G, Moss AJ, Kalaria VG, Marder VJ, Weiss HJ, et al. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators. Thromb Haemost. 2001;86(3):791–9.PubMed Zareba W, Pancio G, Moss AJ, Kalaria VG, Marder VJ, Weiss HJ, et al. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators. Thromb Haemost. 2001;86(3):791–9.PubMed
19.
Zurück zum Zitat Saboor M, Moinuddin, Ajmal M, Ilyas S. Functional status of vascular endothelium in diabetes mellitus. J Ayub Med Coll Abbottabad. 2014;26(2):239–43.PubMed Saboor M, Moinuddin, Ajmal M, Ilyas S. Functional status of vascular endothelium in diabetes mellitus. J Ayub Med Coll Abbottabad. 2014;26(2):239–43.PubMed
20.
Zurück zum Zitat Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens. 2003;16(1):11–20.CrossRefPubMed Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens. 2003;16(1):11–20.CrossRefPubMed
21.
Zurück zum Zitat Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol. 2003;92(4):400–5.CrossRefPubMed Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol. 2003;92(4):400–5.CrossRefPubMed
22.
Zurück zum Zitat Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115(3):520–32.CrossRefPubMed Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115(3):520–32.CrossRefPubMed
23.
Zurück zum Zitat Arslan Y, Yoldaş TK, Zorlu Y. Interaction between vWF levels and aspirin resistance in ischemic stroke patients. Transl Stroke Res. 2013;4(5):484–7.CrossRefPubMed Arslan Y, Yoldaş TK, Zorlu Y. Interaction between vWF levels and aspirin resistance in ischemic stroke patients. Transl Stroke Res. 2013;4(5):484–7.CrossRefPubMed
24.
Zurück zum Zitat Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost. 2009;101(5):929–37.PubMed Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost. 2009;101(5):929–37.PubMed
25.
Zurück zum Zitat Samai A, Monlezun D, Shaban A, George A, Dowell L, Kruse-Jarres R, et al. Von Willebrand factor drives the association between elevated factor VIII and poor outcomes in patients with ischemic stroke. Stroke. 2014;45(9):2789–91.CrossRefPubMed Samai A, Monlezun D, Shaban A, George A, Dowell L, Kruse-Jarres R, et al. Von Willebrand factor drives the association between elevated factor VIII and poor outcomes in patients with ischemic stroke. Stroke. 2014;45(9):2789–91.CrossRefPubMed
26.
Zurück zum Zitat Bath PM, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, P‑selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets. 1998;9(3–4):155–9.PubMed Bath PM, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, P‑selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets. 1998;9(3–4):155–9.PubMed
Metadaten
Titel
Clinical role of von Willebrand factor in acute ischemic stroke
verfasst von
Marija Menih, MD
Miljenko Križmarić, PhD
Tanja Hojs Fabjan, MD, PhD
Publikationsdatum
01.07.2017
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 13-14/2017
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-017-1200-4

Weitere Artikel der Ausgabe 13-14/2017

Wiener klinische Wochenschrift 13-14/2017 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

mitteilungen der gesellschaft der ärzte in wien